arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Scienture Holdings, Inc.

SCNX
$3.10 ▼ -0.33 (-9.74%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
55 Visible periods
30 Metrics
Peer-ranked Benchmarks
Price Chart
20
Health
Poor
Bearish
auto_awesome

Analytical Summary

Scienture Holdings, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $122.8M
Dividend Yield —
Revenue Growth None
Op. Margin None
ROIC -3.3% ↗
FCF / Share $-0.08 ↘
Trailing P/E —
Price / Book 2.0x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

55-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$343.64K
↑ +510.1% —
Net Income Profit after all expenses
$-3.40M
↓ -11.0% —
Operating Margin Operating profit as % of sales
-41.1%
↓ -167.5% —
FCF / Share Free cash flow per share
$-0.08
↓ -10.0% —
Long-Term Debt Long-term obligations
$2.00M
↓ -44.1% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↓
14
Cash Quality ↓
33

bar_chart Data from SEC EDGAR XBRL filings

Synced 5 days ago 14 years · 55 quarters